Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medinet CoTSE:2370 41 Cyclically Adjusted PS Ratio is 2.75 as of Aug. 05, 2026, which is 22% below its 10-year median of 3.54. GuruFocus rates TSE:2370 with a GF Score™ of 41/100 and a GF Value™ of 円41.70 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 538 Biotechnology companies, Medinet Co ranks better than 66.36% on this metric.
The historical rank and industry rank for Medinet Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
TSE:2370'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.43 Med: 3.54 Max: 6.91
Current: 2.75
During the past years, Medinet Co's highest Cyclically Adjusted PS Ratio was 6.91. The lowest was 1.43. And the median was 3.54.
TSE:2370's Cyclically Adjusted PS Ratio is ranked better than 66.36% of 538
companies
in the Biotechnology industry
Industry Median: 5.485
vs TSE:2370: 2.75
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Medinet Co's adjusted revenue per share data for the three months ended in Mar. 2026 was 円0.839. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is 円9.08 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Medinet Co (TSE:2370) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Medinet Co Cyclically Adjusted PS Ratio Related Terms
Medinet Co Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Medinet Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2370 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Medinet Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinet Co Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medinet Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Medinet Co's Cyclically Adjusted PS Ratio falls into.
Medinet Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Medinet Co's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 2.75 mean?
Medinet Co (TSE:2370) has a Cyclically Adjusted PS Ratio of 2.75 as of Aug. 05, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medinet Co and its competitors. This is 22% below median its historical median of 3.54. Over the past decade, Medinet Co's Cyclically Adjusted PS Ratio has ranged from 1.43 to 6.91. According to the industry distribution chart, Medinet Co ranks #181 out of 538 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Medinet Co's Cyclically Adjusted PS Ratio too high?
Medinet Co's current Cyclically Adjusted PS Ratio of 2.75 is 22% below median its 10-year median of 3.54. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 6.91. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.49. Medinet Co's value of 2.75 is 49.9% below this industry median. Based on the distribution chart, Medinet Co ranks #181 out of 538 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medinet Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medinet Co ranks #181 out of 538 companies for Cyclically Adjusted PS Ratio. This puts Medinet Co in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.49. Medinet Co's value of 2.75 is 49.9% below this benchmark. Historically, Medinet Co's own Cyclically Adjusted PS Ratio has ranged from 1.43 to 6.91 over the past decade. While the company's 10-year median is 3.54 vs. the industry median of 5.49, Medinet Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.49, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinet Co's current Cyclically Adjusted PS Ratio of 2.75 is 49.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medinet Co and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinet Co's current Cyclically Adjusted PS Ratio is 2.75, which is 22% below median its own 10-year median of 3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.70, compared to a current price of 円25.00 — trading 40% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 2.75, which is 22% below median its 10-year median of 3.54 and 49.9% below the Biotechnology industry median of 5.49. Medinet Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current Cyclically Adjusted PS Ratio is 2.75 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40% below its estimated GF Value™ of 円41.70.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
Cyclically Adjusted PS Ratio: 2.75 (22% below median its 10-year median of 3.54)
GF Value™: 円41.70 vs. price of 円25.00 (40% below fair value)
Industry Position: 49.9% below the Biotechnology median (#181 of 538)
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
41GF Score
Get the complete analysis for TSE:2370
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
